Quick Dispatch:
Your eccogene glp 1 Eccogene obtains exclusive license from AstraZeneca to develop and sell ECC5004, a GLP-1 receptor agonist for cardio-metabolic diseases orders ship within 1-2 business days.
Delivery Options:
Order Tracking:
You'll receive a tracking link by email once your eccogene glp 1 Eccogene obtains exclusive license from AstraZeneca to develop and sell ECC5004, a GLP-1 receptor agonist for cardio-metabolic diseases ships.
Need Help?
Questions about eccogene glp 1 Eccogene obtains exclusive license from AstraZeneca to develop and sell ECC5004, a GLP-1 receptor agonist for cardio-metabolic diseases, sizing, or delivery? We're just an email away.
Live Shipping Estimates:
Enter your location at checkout to see available shipping methods and costs for eccogene glp 1 Eccogene obtains exclusive license from AstraZeneca to develop and sell ECC5004, a GLP-1 receptor agonist for cardio-metabolic diseases in your area.
Eccogene will present Phase 1b data for elecoglipron (AZD5004/ECC5004), our investigational oral small-molecule GLP-1 receptor agonist, in a late-breaking poster presentation at the American Diabetes…
27.93
Glucagon-Like Peptide-1 Based Therapies: A New Horizon in Obesity Management
23.88
AstraZeneca stays in GLP-1 drug race with new deal
24.61
AstraZeneca raises stakes in obesity drug race with Eccogene deal
27.61
Eccogene files for Hong Kong IPO to boost oral therapy pipeline | Shin-En Peng posted on the topic
21.30
Eccogene Enters Exclusive License Agreement With AstraZeneca to Develop and Commercialize Small Molecule GLP-1 Receptor Agonist ECC5004 for Cardiometabolic Diseases
20.87
Eccogene Reports Positive Phase 1b Results for Oral GLP-1 Candidate Elecoglipron in China
20.27
